|
Post by mango on Mar 6, 2017 20:46:38 GMT -5
The problem MannKind has are doctors are glorified mechanics and patients are too timid to demand a real solution to their condition. You are singing the same song Trials say Afrezza is comparable to 💉 What do you want the docs to do? They are rightfully wary of lung issues It's up to Mannkind to break that and are they doing it? Patients too timid? Do they know Afrezza? Again why is that? What lung issues? Afrezza is the world's only insulin monomer and is also the world's only non-amyloidogenic insulin. All injectable insulins are amyloidogenic and also contain numerous precursors to amyloidosis. They should be worried about that. Anyways, Why is MannKind even still focused on Endo clinics? Family med and acute care clinics literally manage tons of diabetics and family med docs and nurse practitioners are more open-minded and willing to try new innovative treatments, especially non-invasive ones.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 6, 2017 20:55:05 GMT -5
Afrezza did not demonstrate superiority to analogues because of poor trial design. Patients do not have the courage to point out doctor's poor decisions because of their lack of knowledge. Afrezza has no issues except for the FUD created by big pharmaceuticals and Wall Street.
Good luck with trying to fool the rest of so called 'longs' that lend their shares out to be shorted. What a joke!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 6, 2017 21:05:21 GMT -5
Afrezza did not demonstrate superiority to analogues because of poor trial design. Patients do not have the courage to point out doctor's poor decisions because of their lack of knowledge. Afrezza has no issues except for the FUD created by big pharmaceuticals and Wall Street. Good luck with trying to fool the rest of so called 'longs' that lend their shares out to be shorted. What a joke! I end my discussion. I have seen a few threads here and know when to quit
|
|